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of the cathepsin family of cysteine proteases, including cathepsin L, furin, and the serine proteases factor Xa, plasmin, elastase, tryptase, TMPRSS2, and TMPRSS4.
Coronavirus (SARS CoV-2, SARS-CoV, and Middle East
respiratory syndrome coronavirus [MERS]) entry is mediated
by the viral spike protein, which must be cleaved by host proteases in order to trigger membrane fusion and entry into the
host cell after binding to the host cell receptor Angiotensin
Converting Enzyme-2 (ACE2) (7–10). This is mediated by initial cleavage at the S1/S2 junction of spike, which is thought to
occur during processing in the producer cell, followed by cleavage at the S20 site either by serine proteases at the cell surface

Signiﬁcance
MM3122 represents an advanced lead candidate for clinical
development as a novel antiviral drug for COVID-19. In addition to being novel drugs, these selective TMRSS2 inhibitors
can be used as valuable chemical probes to help elucidate
mechanisms of viral pathogenesis. Since TMPRSS2 plays a
key role as a viral protein processing protease in the pathogenesis of other coronaviruses (SARS-CoV, MERS-CoV) as
well as inﬂuenza viruses, MM3122 and this class of TMPRSS2
inhibitors hold much promise as new drugs to not only treat
SARS-CoV-2 infections but also potentially represent broadspectrum antivirals.

antiviral j protease inhibitor j COVID-19 j structure-based drug discovery j
PS-SCL
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evere acute respiratory syndrome coronavirus 2 (SARSCoV-2) is the newly emerged, highly transmissible coronavirus responsible for the ongoing COVID-19 pandemic, which is
associated with 136 million cases and almost 3 million deaths
worldwide as of April 12, 2021 (https://coronavirus.jhu.edu/
map.html). While three vaccines have recently been approved
by the FDA, there are still no clinically approved smallmolecule drugs available for the treatment of this disease
except Remdesivir, and the effectiveness of the vaccines against
immune escape variants might be reduced. Multiple therapeutic
strategies have been proposed (12), including both viral and
host proteins, but none have yet been fully validated for clinical
application. One class of protein targets which have shown
promising results are proteolytic enzymes including the viral
proteases (1, 3–5), Papain-Like Protease (PLpro) and the
3C-like or “Main Protease” (3CL or MPro), and several host
proteases involved in viral entry, replication, and effects on the
immune system creating the life-threatening symptoms of
COVID-19 infection (4–6). The latter include various members
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The host cell serine protease TMPRSS2 is an attractive therapeutic
target for COVID-19 drug discovery. This protease activates the
Spike protein of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) and of other coronaviruses and is essential for viral
spread in the lung. Utilizing rational structure-based drug design
(SBDD) coupled to substrate speciﬁcity screening of TMPRSS2, we
have discovered covalent small-molecule ketobenzothiazole (kbt)
TMPRSS2 inhibitors which are structurally distinct from and have
signiﬁcantly improved activity over the existing known inhibitors
Camostat and Nafamostat. Lead compound MM3122 (4) has an
IC50 (half-maximal inhibitory concentration) of 340 pM against
recombinant full-length TMPRSS2 protein, an EC50 (half-maximal
effective concentration) of 430 pM in blocking host cell entry into
Calu-3 human lung epithelial cells of a newly developed VSVSARS-CoV-2 chimeric virus, and an EC50 of 74 nM in inhibiting cytopathic effects induced by SARS-CoV-2 virus in Calu-3 cells. Further,
MM3122 blocks Middle East respiratory syndrome coronavirus
(MERS-CoV) cell entry with an EC50 of 870 pM. MM3122 has excellent metabolic stability, safety, and pharmacokinetics in mice, with
a half-life of 8.6 h in plasma and 7.5 h in lung tissue, making it suitable for in vivo efﬁcacy evaluation and a promising drug candidate
for COVID-19 treatment.
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or by cathepsin proteases in the late endosome or endolysosome (9, 10). Whether serine or cathepsin proteases are used
for S20 cleavage is cell type dependent. While entry into Calu-3
(human lung epithelial) or HAE (primarily human airway epithelial) cells is cathepsin independent, entry into Vero cells
(African green monkey kidney epithelial), which do not express
the required serine proteases, depends exclusively on cathepsins (7, 9–11).
TMPRSS2 (12) is a type II transmembrane serine proteases
(TTSP) (13) that has been shown to be crucial for host cell viral
entry and spread of SARS-CoV-2 (7, 8, 14–16), as well as
SARS-CoV (17, 18), MERS-CoV (19), and influenza A viruses
(20–27). The Spike protein requires proteolytic processing/
priming by TMPRSS2 to mediate entry into lung cells; thus,
small-molecule inhibitors of this target offer much promise as
new therapeutics for COVID-19 and other coronavirus diseases
(7, 8). TMPRSS2 expression levels dictate the entry route used
by SARS-CoV-2 to enter cells, as reported recently (28).
In cells that express little or no TMPRSS2, cell entry occurs via
the endosomal pathway, and cleavage of spike protein is performed by cathepsin L. It has been demonstrated that the
TMPRSS2-expressing lung epithelial Calu-3 cells are highly
permissive to SARS-CoV-2 infection. The irreversible serine
protease inhibitors Camostat (7) and Nafamostat (29) are
effective at preventing host cell entry and replication of SARSCoV-2 in Calu-3 cells through a TMPRSS2-dependent mechanism (14, 15).
Herein, we report on the discovery of a class of substratebased ketobenzothiazole (kbt) inhibitors of TMPRSS2 with
potent antiviral activity against SARS-CoV-2 which are significantly improved over Camostat and Nafamostat. Several compounds were found to be strong inhibitors of viral entry and
replication, with EC50 (half-maximal effective concentration)
values exceeding the potency of Camostat and Nafamostat and
without cytotoxicity. Newly developed compound MM3122 (4)
has excellent pharmacokinetics (PK) and safety in mice and is
thus a promising lead candidate drug for COVID-19 treatment.
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Results and Discussion
Hit Identification of TMPRSS2 Inhibitors. It is well established that
several TTSPs including TMPRSS2 play a role not only in
infectious diseases (12) but also in cancer progression and
metastasis (30–32) which is thought to be mainly through their
ability to activate hepatocyte growth factor (HGF), the sole
ligand for MET receptor tyrosine kinase. This is accomplished
via proteolytic processing of the inactive single-chain precursor
pro-HGF to a two-chain active form. TMPRSS2 shares proHGF as a protein substrate with the other HGF-activating serine proteases, HGFA (HGF-Activator), hepsin, and matriptase
(33, 34). Like TMPRSS2, other TTSPs such as matriptase and
hepsin have a canonical serine protease domain residing as the
C-terminal domain of the protein that is anchored to the cell
membrane by an N-terminal type II signal peptide, thereby presenting their enzymatic activity outside the cell. We have previously reported on the discovery and anticancer properties of
peptidomimetic ketothiazole (kt) and kbt inhibitors of HGFA,
matriptase, and hepsin (35–39) named synthetic HGF Activation Inhibitors or sHAIs. Since TMPRSS2 has an overlapping
endogenous substrate specificity profile with HGF-activating
proteases, we postulated that our substrate-based sHAIs would
also inhibit TMPRSS2.
Antiviral activity of sHAIs (VSV/SARS-CoV-2 spike protein pseudotypes). Based on our premise that sHAIs would inhibit TMPRSS2,

we first selected the two sHAI lead compounds, ZFH7116 (1) (37,
40) and VD2173 (2) (Fig. 1), for initial antiviral testing and confirmed that they potently inhibit TMPRSS2-dependent host cell
viral entry driven by the spike protein of SARS-CoV-2 (SARS-2 S;
2 of 12 j PNAS
https://doi.org/10.1073/pnas.2108728118

Fig. 1. Structures of the initial of TMPRSS2 inhibitors discovered by screening existing HGFA, matriptase, and hepsin serine protease inhibitors.

Fig. 2A) into Calu-3 lung epithelial cells having an EC50 of 307
and 104 nM, respectively. Marked inhibition of SARS-2 Sdriven
entry was also detected for the irreversible inhibitor Camostat, in
line with published data (7, 29). It is noteworthy that neither
compound showed activity in TMPRSS2-negative Vero cells or
modulated entry into Calu-3 cells by pseudotypes bearing the VSV
glycoprotein (VSVpp VSV-G) (SI Appendix, Fig. S6), suggesting
that the inhibition of SARS-CoV-2 spike-driven entry into Calu-3
cells was due to blockade of TMPRSS2.
Antiviral activity of sHAIs (VSV/SARS-CoV-2 spike protein chimeras). Using a replication-competent, chimeric VSV expressing

the SARS-CoV-2 Spike [shown to mimic the Spike-dependent
entry of authentic SARS-CoV-2 (41)], we also demonstrated
that 1 and 2 block viral entry into Calu-3 cells in a dosedependent manner. Both drugs displayed EC50 values of 459
and 197 nM against the chimeric virus VSV-SARS-CoV-2 (Fig.
2B) compared to the pseudotyped virus (Fig. 2A), while showing no activity against VSV-eGFP (VSV Gdependent entry),
or against either virus in Vero cells (SI Appendix, Fig. S7),
which are TMPRSS2 negative. This confirms our initial result
and allows for the establishment of a system for screening antiviral activity of these inhibitors using VSV-SARS-CoV-2.
Inhibition of cell-bound TMPRS2 enzymatic activity by sHAIs. We
tested the inhibitory activity of 1 and 2 on TMPRSS2 proteolytic activity in a cell-based enzyme-based fluorogenic assay, by
overexpression of TMPRSS2 in a human cell line, HEK-293T,
commonly used for experimentation because of its high transfectability. As previously demonstrated, expression of TMPRSS2 can
be accurately measured (42, 43) using a fluorogenic peptide
reporter substrate, Boc-QAR-AMC, in cell cultures. Compound 1
inhibited cell-based TMPRSS2 enzyme activity in a concentrationdependent manner between 10 μM and 10 nM, with an IC50 (halfmaximal inhibitory concentration) of 314 nM (SI Appendix, Fig.
S4). Compound 2 was a more potent inhibitor of TMPRSS2 proteolytic activity, with an IC50 of 57 nM. These data confirm that
both 1 and 2 mediate their function by potently inhibiting TMPRSS2.
Selectivity data of TMPRSS2 inhibitors in a panel of proteases.

We profiled 1 and 2 for their selectivity against a panel of 43
serine and cysteine proteases (SI Appendix, Tables S1 and S2)
for comparison to that of Camostat and Nafamostat protease
selectivity data which have been published (44). We found 1
was a potent inhibitor of matriptase-2, plasma kallikrein, proteinase K, trypsin, tryptase b2, and G1 but also was a moderate
Mahoney et al.
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV
viral entry and protect human epithelial lung cells

MEDICAL SCIENCES
Downloaded at SCHL MED LIB&77680003 on December 17, 2021

inhibitor of factor Xa, factor XIIa, and kallikreins 5 and 14, as
well as cysteine protease cathepsin S, while showing some activity against cathepsin L as well. There was overlap of 1 with the
selectivity profiles of Camostat, except they did not show any
activity against the cathepsins. Furthermore, Camostat more
potently inhibited factor XIIa, plasma kallikrein, matriptase-2,
and plasmin, while also having increased activity for trypsin, the
tryptases, and urokinase. Cyclic peptide 2 also more potently
inhibited urokinase and factor XIIa relative to 1 but not
cathepsin S or L, and instead was a moderate inhibitor of
cathepsin B. The ramifications of these different selectivity profiles may explain the varied activity in the VSV-pseudotype and
chimeric viral entry results most notably the urokinase potency
for which 1 was significantly weaker.
Lead Identification of TMPRSS2 Inhibitors. We published (38) that
Camostat and Nafamostat (Fig. 3B) are inhibitors of matriptase
and hepsin, and analog Nafamostat is the most active published
inhibitor of SARS-CoV-2 cell entry (8). While we previously
pursued this chemical series as HGFA, matriptase, and hepsin
inhibitors (38), the best series we have developed are small
peptide-based molecules like 1, 2, and 3 (Ac-SKLR-kbt; Fig.
3B) which exhibit low nanomolar to picomolar IC50s. These
compounds contain a serine-trapping kbt warhead (35–37, 39)
which reacts covalently with the protease, but, importantly, in a
reversible manner, unlike Camostat or Nafamostat, in which
the inhibition is irreversible. Therefore, we pursued the kbt
Mahoney et al.
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV
viral entry and protect human epithelial lung cells

class of inhibitors for lead identification studies toward more
potent and selective TMPRSS2 inhibitors.
Rational design of TMPRSS2-selective kbt inhibitors. We have
employed X-ray cocrystal structure data in the rational design
of optimized HGFA, matriptase, and hepsin inhibitors with
increased potency and selectivity (35–38). Shown in Fig. 3, here
we used a homology model of human TMPRSS2 (45) to computationally model our existing inhibitors (using Glide in
Schr€
odinger) where we docked compound 3 (yellow; Fig. 3A)
and Nafamostat (gray). For Nafamostat, the naphthyl portion
extends deep into the S2 pocket, with the benzguanidine in the
S1 pocket binding to the conserved S1 Asp189. The P4 Ser of 3
makes two H bonds to Asp162 and Asn163 outside the S4
pocket, and the Ser backbone carbonyl is also within
H-bonding distance of the P2 Lys98. The P3 Lys is near the S4
Glu134 making an electrostatic interaction, while the P2 Leu
resides in the S2 pocket, and the benzothiazole fills the S10
area. The reactive ester of Nafamostat and ketone of the kbt
are adjacent to the Ser195His57Asp102 catalytic triad. Our
model of 3 and Nafamostat bound to TMPRSS2 (Fig. 3A)
shows a nice fit to the S1 through S4 and S10 pockets of
TMPRSS2. For 3, it appears that the P4 Ser is making a dual
H bond to the Asp162 and Asn163 residues in TMPRSS2.
This area is occupied by a Gln in both hepsin and matriptase
but by an Asp in HGFA, and, interestingly, the additional
Asn163 residue is unique to TMPRSS2. This suggests that a
free amine in the P4 could provide selectivity over matriptase
and hepsin. The structure also shows that Lys87 resides in the
PNAS j 3 of 12
https://doi.org/10.1073/pnas.2108728118
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Fig. 2. Inhibition of SARS-CoV-2 cell entry into Calu-3 lung epithelial cells by ZFH7116 (1) and VD2173 (2) using (A) VSV-SARS-CoV-2-Spike protein Pseudotype virus and (B) VSV-SARS-CoV-2-Spike protein Chimeric virus. EC50s are calculated from an average of three separate experiments. Statistics compare
relative infection at each concentration (*P < 0.05, **P < 0.01, ***P < 0.001, Student's t test). Camostat was used as a positive control.
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side chain binds (46). Red color designates overlap of TMPRSS2 amino acid
speciﬁcity with other proteases. Single letter designations for amino acids
are shown.
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Fig. 3. (A) Molecular docking model of compound 3 (yellow) and Nafamostat (gray) bound to a homology model of TMPRSS2 using Glides/
€ dinger. (B) Structures of compound 3, Camostat, and Nafamostat.
Schro

S2 pocket, suggesting a P2 Glu or Asp might be ideal for an
inhibitor of TMPRSS2 and lead to potential selectivity over
HGFA (P2 Ser), matriptase (P2 Phe), and hepsin (P2 Asn).
This Lys87 is also near the P4 Ser side chain, indicating an Asp
or Glu in this position could potentially make a third electrostatic interaction with Lys87. Further, the S2 pocket is large
and appears able to accommodate larger side chains such as
Phe, Tyr, or Trp.
PS-SCL protease substrate specificity profiling of TMPRSS2. To
augment our rational design of more potent and selective
TMPRSS2 inhibitors, we analyzed existing data on the peptide
substrate preferences of TMPRSS2, HGFA, matriptase, and
hepsin. When comparing the positional scanning of substrate
combinatorial libraries (PS-SCL) data of TMPRSS2 (Fig. 4)
(30) with that of matriptase (47), hepsin (48), and HGFA
(36), it became apparent that there was significant overlap
in their preferences for substrates. These data reveal that
TMPRSS2 is tolerant of many different P2 side chains but
prefers Phe and Ala/Thr like matriptase (Fig. 4), which can
also tolerate both large and small groups (prefers Ser/Ala),
4 of 12 j PNAS
https://doi.org/10.1073/pnas.2108728118

but hepsin and HGFA both prefer Leu. For P3, TMPRSS2
prefers Gln/Glu and Met, whereas Lys/Gln is preferred for
hepsin and matriptase, and Lys/Arg is preferred for HGFA
(Fig. 4). The clearest distinction is in the P4 position, where
HGFA, matriptase, and hepsin all prefer basic residues like
Lys/Arg, while TMPRSS2 prefers Ile/Gly and Pro, which is a
shared attribute with hepsin.
Multiplex substrate profiling by mass spectrometry profiling
of TMPRSS2 for extended substrate sequence specificity. To

strengthen our compound design, we obtained further information on the extended substrate specificity of TMPRSS2 using
multiplex substrate profiling by mass spectrometry (MSP-MS)
(49). In the MSP-MS assay, a physiochemically diverse library
of 228 tetra decapeptides was incubated for several hours with
human recombinant TMPRSS2 in activity buffer. At different
time points (15, 60, and 240 min), aliquots of the reaction mixture were extracted, quenched with 8 M guanidium HCl, and
analyzed by tandem MS to allow monitoring of proteasegenerated cleaved products. As a TTSP with a trypsin fold,
TMPRSS2 is known for its high affinity toward substrates containing an arginine residue in the P1 position (30). This prominent P1 specificity was confirmed by our MSP-MS analysis,
which showed a nearly exclusive occupancy of the P1 position
by either Arg or Lys on TMPRSS2-generated cleaved products
(Fig. 5A). Peptide sequencing by LC-MS/MS enabled the
identification of the 25 most preferred substrates for TMPRSS2
in our peptide library (Fig. 5B). An IceLogo frequency plot
(Fig. 5C) displays the extended substrate specificity profile of
TMPRSS2 at pH 7.5, which reveals the preference for hydrophobic amino acids in both P2 and P10 positions, which flank
the cleavage site. The analysis indicates a preferred cleavage of
N-terminal tetrapeptides to be PLFR with other P4 amino
acids H and M and P3 amino acids G, Y, V, and Q but only
F at P2, which is striking. Largely, these data recapitulate
what was elucidated in the PS-SCL study (Fig. 4). Based on
careful analysis of the computational modeling work with
these and the PS-SCL results, we selected additional existing
compounds in our library of HGFA/matriptase hepsin inhibitors for testing and synthesized (SI Appendix, Schemes S1–S3)
four analogs specifically designed for TMPRSS2: Ac-GQFRkbt (4), Ac-PQFR-kbt (5), Ac-QFR-kbt (6), and Ac-IQFRkbt (7).
Inhibition of VSV-SARS-CoV-2 viral entry. Analogs based on the
initial hit compounds 1 and 2 along with the substrate specificity data were Ac-SKLR kbt (3), Ac-WFR-kbt (8), Ac-SKFR-kt
(9), Ac-KQFR-kt (10), Ac-SQLR-kt (11), Ac-FLFR-kbt (12),
Ac-dWFR-kbt (13), dWFR-kbt (14), dWFR-kbt-CO2H (15),
Ac-WLFR-kbt (16), Ac-KQLR-kbt (17), Ac-LLR-kt (18),
Mahoney et al.
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study, while others contain a Gln (Q) at the P3 position. When
tested in the VSV pseudotype assay, all displayed improved
activity relative to 1 (Table 1), where the best compound was

Table 1. Structures and inhibition data of compounds for protease enzyme activity and VSV pseudotype and chimera SARS-CoV-2
viral entry into human Calu-3 lung epithelial cells

Downloaded at SCHL MED LIB&77680003 on December 17, 2021

Name/structure
Remdesivir
Camostat
Nafamostat
Ac-SKLR-kbt-V (1)
Cyclo(DLK)R-kbt (2)
Cyclo(DMK)R-kbt
(19)
Cyclo(aGLY)R-kbt
(21)
Cyclo(DQK)R-kbt (20)
Ac-WFR-kbt (8)
Ac-SKFR-kt (9)
Ac-KQFR-kt (10)
Ac-SQLR-kt (11)
Ac-LLR-kt (18)
Ac-SKLR-kbt (3)
Ac-FLFR-kbt (12)
Ac-dWFR-kbt (13)
dWFR-kbt (14)
dWFR-kbt-CO2H (15)
Ac-WLFR-kbt (16)
Ac-KQLR-kbt (17)
Ac-IQFR-kbt (7)
Ac-QFR-kbt (6)
Ac-PQFR-kbt (5)
Ac-GQFR-kbt (4)

Factor Xa
IC50 (nM)

VSV-SARSCoV-2
VSV-SARSChimera
CoV-2 Calu- Calu-3 EC50
3 EC50 (nM)
(nM)

SARS-CoV-2
Wild-type
Calu-3 IC50
(nM)

TMPRSS2
IC50 (nM)

HGFA IC50
(nM)

Matriptase
IC50 (nM)

Hepsin IC50
(nM)

Thrombin
IC50 (nM)

NA
1.5
0.14
74
2.6
19

NA
>20,000
158
23
8520
3240

NA
7.0
0.05
14
2.6
1.0

NA
7.0
0.9
1.0
19
5.9

NA
>20,000
5,020
7530
8140
18,500

NA
>20,000
4,570
514
2,050
1,390

ND
83
ND
307
104
119

ND
21
ND
489
197
ND

1,271
ND
220*
ND
660
ND

197

>20,000

14

20

>20,000

8,810

565

ND

ND

ND
9.4
7.9
29
16
54
39
3.0
1.1
39
42
6.3
ND
0.25
0.31
0.28
0.34

16,100
329
114
116
364
506
66
228
27
ND
ND
266
60
30
14
75
32

7.7
5.7
6.1
1.4
18
56
6.1
7.2
2.6
ND
ND
12
1.1
0.92
0.13
0.32
0.31

22
7.6
17
1.2
0.68
4.6
0.32
2.9
1.1
ND
ND
0.79
0.17
0.14
0.08
0.13
0.19

>20,000
>20,000
>20,000
>20,000
ND
ND
>20,000
>20,000
3,700
ND
ND
>20,000
>20,000
>20,000
>20,000
>20,000
>20,000

>20,000
22
1,060
158
ND
ND
3,800
26
98
ND
ND
2.0
258
792
1.4
199
700

138
ND
ND
ND
ND
349
ND
ND
32
ND
ND
150
78
ND
ND
ND
ND

ND
1,377
1,157
262
1,320
1,838
4,272
101
ND
357
105
ND
572
3.6
0.53
0.86
0.43

ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
102
105
52
74

ND, not determined; NA, not applicable.
*Here, n = 1.
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Cyclo(DMK)R-kbt (19), Cyclo(DQK)R-kbt (20), and Cyclo(allylGLY)R-kbt (21). Many of these compounds contain a Phe
(F) residue in the P2 position as predicted from the PS-SCL

CHEMISTRY

Fig. 5. (A) Heatmap displaying the overall amino acid frequencies in each of the P4P40 positions of a positive set of peptides cleaved by human
TMPRSS2. Positive enrichment is observed as red, and zero was set to yellow. (B) Total spectral counts determined by LC-MS/MS highlight peptide sequences as high turnover rates substrates for TMPRSS2. (C) IceLogo depicting the extended substrate speciﬁcity of human TMPRSS2 based on 205 cleavage
events detected through MSP-MS analysis.

Fig. 6. Structures of rationally designed covalent reversible kbt inhibitors (4 through 7) of TMPRSS2.

13. Compound 13 is a tripeptide containing an unnatural amino
acid D-Trp in the P3 position and Phe in the P2 position, predicted from PS-SCL and MSP-MS analysis to be preferred.
Compound 17, which contains a P3 Gln also predicted from
PS-SCL, shows the next best activity, with an EC50 of 78 nM.
Furthermore, 16, also having a P2 Phe, showed an excellent
potency of 150 nM. Corresponding cycloamide analogs of 2, 19,
and 20 retained good activity (EC50 of 119 and 138 nM) for inhibition of viral entry of the VSV pseudotype, but allyl phenyl ether
analog 21 showed a significant decrease in activity (EC50 565 nM).
The remaining compounds were tested in the VSV-SARSCoV-2 chimeric assay. Excitingly, the most promising results
(Table 1) were derived from our new rationally designed
TMPRSS2 inhibitors, 4 through 7. These compounds were
designed by incorporating the preferred side chains (as determined from PS-SCL data above) at all the P1 through P4 positions of the inhibitor. The set of existing compounds all showed
good potency, with the best, 12, showing an EC50 of 101 nM in
blocking viral entry of VSV-SARS-CoV-2 chimeras into Calu-3
cells, sixfold more active than the second-best analog in the
pseudotype assay, 17. Excitingly, three of the new rationally
designed analogs, 4 through 6, displayed significantly increased
potency (Fig. 6), with subnanomolar EC50s, and the fourth new
compound, 7, is still extremely potent, with an EC50 of 3.6 nM.
This not only constitutes a 230-fold increase in activity for 4
(EC50 0.43 nM) relative to the previous best compound, 12, but
also an 80-fold improvement over Camostat. Of the other compounds, similar potency compared to 12 was seen from tripeptide 15 (EC50 105 nM) but less so from 14, analogs of 13, which
was the best compound tested in the pseudotype assay. Also
showing excellent potency is 10, with an EC50 of 262 nM.

Table 2. Activity of lead compounds against VSV pseudotype
MERS viral entry into human Calu-3 lung epithelial cells
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MERS VSV
Mouse plasma
pseudotype
stability
Human plasma
Name/structure Calu-3 EC50 (nM)
t1/2 (min)
stability t1/2 (min)
Camostat
2 (VD2173)
7 (MM3116)
6 (MM3144)
5 (MM3123)
4 (MM3122)

5.0
273
2.3
0.55
2.9
0.87

ND
222
154
>289
>289
>289

ND
>289
>289
>289
>289
>289

Also shown is the plasma stability of selected compounds in both mouse
and human plasma.
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Inhibition of VSV-MERS viral entry. To demonstrate broad coronavirus activity, we tested Camostat, 2, and our best new compounds, 4 through 7 (Fig. 6), based on the VSV chimera results
for their activity in blocking host cell entry of a MERS-CoV
chimeric virus. Shown in Table 2, all compounds inhibited
MERS-CoV viral entry with nearly equivalent potency as compared to SARS-CoV-2 (Table 1). Although the TMPRSS2
dependence of MERS-CoV has been demonstrated previously,
this provides strong evidence that our compounds have broadspectrum potential against other coronaviruses in the clinic. To
confirm that this activity is indeed TMPRSS2 related, we next
set out to produce recombinant TMPRSS2 protein for testing
our compounds for their enzyme inhibitory activity.
Expression and purification of recombinant TMPRSS2 (protease
domain). Recombinantly expressed TMPRSS2 protease domain

(SI Appendix, Fig. S8A) was purified via Ni-nitrilotriacetate
(NTA) column (SI Appendix, Fig. S8C), then verified by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS/
PAGE) and Western blot (SI Appendix, Fig. S8 D and E), showing no presence of other proteins. Catalytic activity was tested
by combining 150 nM of purified TMPRSS2 protease domain
with (MCA)-K-KARSAFA-K-(DnP), an 8-mer peptide fluorescence resonance energy transfer (FRET) substrate that was
synthesized based on the peptide that was most efficiently preferred by TMPRSS2 from our MSP-MS analysis (Fig. 5).
MichaelisMenten kinetics showed a Km of 0.6 6 0.05 μM (SI
Appendix, Fig. S8B). Relative to the full-length TMPRSS2 (see
below), the kcat (catalytic rate constant) value achieved for the
protease domain (0.07/s) was 1,000-fold lower than that
observed for the construct bearing the LDLR class A domain
and scavenger receptor cysteine-rich (SRCR) modules
N-terminal to the catalytic domain (kcat = 94.54/s). Further
investigations are necessary to understand these differences
and the interactions among the catalytic domain, the LDLR,
and the SRCR domains that impact the extended specificity
and, potentially, the catalytic activity of TMPRSS2.
Recombinant TMPRSS2 (full-length) enzyme assay. Using active
recombinant full-length TMPRSS2 as described above, along
with Boc-QAR-AMC as a fluorogenic substrate (44), we found
the Km (Michaelis constant) was 85.6 μM using an enzyme
concentration of 3 nM (SI Appendix, Fig. S2). We used this
substrate to test all inhibitors for inhibition of TMPRSS2 proteolytic enzyme activity in a standard kinetic assay using Nafamostat and Camostat as controls, where we determined the
compound IC50s over the period of 1 h, following 30-min compound incubation with enzyme. The IC50 values for Camostat
and Nafamostat are 1.5 and 0.14 nM, which is similar but
slightly improved compared to values previously reported of 6.2
Mahoney et al.
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV
viral entry and protect human epithelial lung cells
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Antiviral activity of lead compounds (wild-type SARS-CoV-2).

After confirming and quantitating TMPRSS2 enzyme inhibition
of all compounds against recombinant protein and their selectivity over HGFA, matriptase, hepsin, thrombin, and Factor Xa,
we assessed the activity of our most promising lead compounds
2 and 4 through 7 in inhibiting the cytopathic effects of wildtype SARS-CoV-2 by employing a CellTiter-Glo (Promega) cellular viability assay with lung epithelial Calu-3 cells (50). We
used Remdesivir and Nafamostat (n = 1) as positive controls.
While all compounds showed excellent activity in this assay
(Fig. 7 and Table 1), the most potent compounds were the
rationally designed TMPRSS2 inhibitors 4 and 5 (Fig. 6), with
EC50s of 74 and 52 nM, respectively, which is >20-fold
improved over Remdesivir and also significantly more active
than Nafamostat (note that this is based on n = 1). Importantly,
all five kbt inhibitors showed no signs of toxicity to Calu-3 cells
(up to 50 μM, which is nearly 1,000 times the IC50 for 5), while
Remdesivir and Nafamostat displayed toxicity at the highest
concentration tested (50 μM).

Fig. 7. (A) Inhibition of the cytopathic effects (viral toxicity) of wild-type SARS-CoV-2 Calu-3 by lead TMPRSS2 inhibitors using the CellTiter-Glo (Promega)
assay. (B) Viability of Calu-3 cells with compounds in the absence of virus (compound toxicity).
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TMPRSS2 prefers large groups extending beyond the kbt S10
C-terminal portion of the inhibitor, since 1 has increased activity relative to unsubstituted kbt analog 3. Strengthening this
hypothesis, the compounds with the smaller kt warhead in the
P10 position like seen in 9 through 11 also lose potency relative
to analogs with larger kbt. Also, the P3 position is important
for activity where it seems basic groups like Lys (K) are undesired (9, 3, 1), which seems also true for the P4 position as seen
with compound 17. Finally, as predicted from modeling and the
PS-SCL data, Phe is clearly preferred in the P2 position. Therefore, it is likely that diverse new analogs can be pursued with
other aromatic side chains like Trp and Tyr, which will also produce inhibitors with exquisite TMPRSS2 activity and potentially
more selectivity.
Given that the homology model of TMPRSS2 used in this
study was exclusive to the catalytic domain of TMPRSS2, both
catalytic domain and full length TMPRSS2 were tested against
candidate compounds. The inhibition IC50 values against the
recombinant protease domain (SI Appendix, Fig. S1) versus
full-length TMPRSS2 show strikingly different values, with estimated IC50s being over 100 μM compared to picomolar to
double-digit nanomolar IC50 values for the commercial fulllength TMPRSS2 (Table 1 and SI Appendix, Fig. S3). It is not
clear, from our current studies, what the direct cause of this
noticeable difference is, but we suspect that the protein
domains/modules of TMPRSS2 which are N-terminal to the
catalytic domain play an important role in ligand interactions
and subsequent catalysis.
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https://doi.org/10.1073/pnas.2108728118

CHEMISTRY

and 0.27 nM, respectively (44). We found the IC50 data we generated for TMPRSS2 inhibition closely correlated with the
VSV pseudotype and chimera assay data, with some exceptions.
Multiple compounds were significantly more potent than
Camostat, and several were equipotent to Nafamostat (Table
1). The new rationally designed lead compounds 4 through 7
(Fig. 6) all displayed exquisitely potent subnanomolar IC50 values of which 7 was the best, with an IC50 of 250 pM, similar to
that of Nafamostat. It should be noted, however, that Nafamostat is an irreversible inhibitor, while the kbt class of inhibitors
are reversible, so it is difficult to directly compare IC50 values
between the two series having different mechanisms of inhibition. While the initial hit compound 1 still shows good potency
against TMPRSS2 (IC50 of 74 nM), it was significantly weaker
when compared to the rationally designed TMPRSS2 inhibitors, which was expected. However, the other initial hit compound 2 is a much more potent inhibitor of TMPRSS2 activity
than 1, with an IC50 of 2.6 nM, only about 10-fold less active
than 4 through 7. It is noteworthy that the P3 to P1 tripeptide 6
without the P4 side chain was almost as active as any of the tetrapeptides 4, 5, or 7 which have a P4 residue. However, this
compound 6 and the other tripeptides, including 8 and 13, suffer from high inhibition of the plasma protease Factor Xa
which is undesirable for further drug discovery due to potential
bleeding side effects in patients.
The least active compound was the aryl ether cyclic peptide
21, with an IC50 of 197 nM, which is, however, still respectable.
It is presumed the larger, more constrained aryl ether ring system is not an ideal fit for binding to the TMPRSS2 active site
through bridging the S2-S4 pockets. It is important to note
that, while TMPRSS2 activity is potent in all inhibitors, most
compounds tested are all still relatively active against the other
proteases HGFA, matriptase, and hepsin.
The most selective TMPRSS2 analogs are 16, with an IC50 of
6.3 nM, being 40-fold more active than HGFA, twofold over
matriptase, and 12, which is 60-fold more selective over HGFA
and twofold against matriptase. As with other compounds in
this series of peptidyl kbt inhibitors, in our experience, we have
found that deriving selectivity over hepsin is challenging, but
one of our best examples turns out to be initial hit 2, which is
fourfold more active against TMPRSS2 relative to hepsin and
almost 10-fold more active against matriptase. The consequences of inhibiting these other serine proteases, especially the
other HGF-activating proteases, in the COVID-19 scenario are
unclear at this time but may be beneficial for treatment rather
than detrimental.
There are clear structureactivity relationships (SAR) from
the 21 compounds tested. For example, it appears that

Fig. 8. Mouse PK of MM3122 (4) and VD2173 (2) after IP dosing at 16.7 mg/kg. Compound concentrations over time in plasma and lung tissue are shown
relative to the IC50 of the compounds in the SARS-CoV-2 VSV hybrid cell entry assay. MM3122 (4) has a half-life (t1/2) of 8.6 h in plasma and 7.5 h in the
lung, and 2.5 h and 4.2 h, respectively for VD2173 (2). Dashed lines indicate the IC50 of compounds in the VSVSARS-CoV-2 cell entry assay.
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PK and metabolic stability of VD2173 (2) and MM3122 (4). Compound 2 (VD2173) and lead compounds 4 through 7 were
tested for their in vitro stability in mouse and human blood
plasma (Table 2). All compounds have excellent stability in
both mouse and human plasma, with >289 min half-life, except
for 7, which had a half-life of 154 min in mouse plasma, and 2,
with a 222-min half-life. Based on potency, selectivity, and in
vitro properties, compound 4 (MM3122) and compound 2
(VD2173) were selected as lead candidates and were tested for
their in vivo PK in mice. Compounds 5 through 7 were not
tested for PK, due their lower antiviral activity and the relatively high Factor Xa activity of 5 and 6. Shown in Fig. 8,
VD2173 (2) has a half-life of 2.5 h in mice with a high area
under the curve (AUC) and exposure in plasma beyond 24 h.
Excitingly, rationally designed TMPRSS2 lead compound
MM3122 (4) also had excellent PK, with a half-life of 8.6 h in
plasma. Both VD2173 and MM3122 were subsequently tested
for their lung exposure over a period of 24 h after intraperitoneal (IP) dosing. It was found that both compounds attained
high levels of compound in the lung and had excellent AUC
but with MM3122 being superior, with a 7.5-h half-life versus
4.2 h for VD2173. The potency of MM3122 versus VD2173 in
both the TMPRSS2 enzyme assay and viral assays is magnitudes higher (500-fold), making MM3122 an ideal lead candidate drug suitable for in vivo efficacy studies of COVID-19 and
further optimization to be reported in a future communication.
Acute 7-d toxicity study of MM3122 (4) in mice. We further tested
lead compound MM3122 for its safety in mice. MM3122 was
administered daily to mice at three different single dose levels
of 20, 50, and 100 mg/kg via IP injection over a period of 7 d.
No adverse effects were observed in any of the treatment
groups, and no weight loss or changes to harvested organs
(liver, spleen, and kidneys) were noted compared to the control
group (SI Appendix, Fig. S5).

Conclusions
TMPRSS2 has been shown to be essential for host cell viral
entry and replication of SARS-CoV-2 as discussed above.
Based on molecular docking studies using a published homology model of TMPRSS2 (45) and substrate specificity data
from PS-SCL, we hypothesized that a set of our existing peptidyl kbt inhibitors of HGFA, matriptase, and hepsin would
also inhibit TMPRSS2. Indeed, we demonstrated that these
compounds potently inhibit not only TMPRSS2 enzyme activity
of recombinant and cell-surface protein, but also host cell entry
and toxicity driven by the Spike protein of SARS-CoV-2 into
ACE2/TMPRSS2-expressing Calu-3 lung epithelial cells. After
further optimization, we identified multiple potent inhibitors of
8 of 12 j PNAS
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TMPRSS2, with four analogs rationally designed for TMPRSS2
displaying subnanomolar activity both in the enzyme assay and
in blocking the entry of VSV-SARS-CoV-2 chimeras into
human Clau-3 epithelial lung cells. In addition, several of these
compounds displayed excellent potency against MERS, another
prominent coronavirus. We further confirmed potent antiviral
activity against the wild-type SARS CoV-2 virus with five lead
compounds, thus identifying the most promising lead compound MM3122 (4). We have clearly established that this
TMPRSS2 inhibitor MM3122 is more potent than Remdesivir,
Camostat, and Nafamostat. Importantly, this compound also
shows no toxicity to Calu-3 cells, in contrast to Remdesivir and
Nafamostat, which are toxic at higher concentrations. MM3122
has excellent metabolic stability in both mouse and human
plasma as well as outstanding PK and safety in mice. Cyclic
peptide VD2173 (2) and rationally designed TMPRSS2 inhibitor MM3122 both have an impressive >8-h half-life in mice. In
addition to its excellent TMPRSS2 inhibition, PK, and antiviral
activity, VD2173 has anticancer efficacy in animal models of
lung cancer. Judging from the protease selectivity data and
potency of MM3122 and other new compounds, these are predicted to also show corresponding anticancer activity, in particular for HGF-driven prostate cancer for which TMPRSS2 is
known to play a key role (30, 51).
Recent studies have identified other TMPRSS family serine
proteases that can mediate SARS-CoV-2 entry, including
TMPRSS13 (293T-ACE2 and Calu-3 cells) (9, 52, 53) and
TMPRSS4 (enteroid cells) (16). Although entry in Calu-3 cells
is far less dependent on TMPRSS13 than TMPRSS2 (9, 28),
the mechanistic contributions and/or redundancies of these
proteases for SARS-CoV-2 entry are not known, nor is their
relative inhibition resolved in the scope of this study. Future
work in animal models, which can resolve the biological and
tissue-specific relevance of protease inhibition, is best poised to
answer these questions.
MM3122 represents an advanced lead candidate for clinical
development as a novel antiviral drug for COVID-19 and
against infections caused by other coronaviruses like MERS in
which we showed equipotent activity of MM3122. We are currently optimizing MM3122 and this class of inhibitors for
TMPRSS2 selectivity and antiviral potency and, in due course,
will test MM3122 and other optimized leads in appropriate animal models of COVID-19. In addition to being novel drugs,
selective TMRSS2 inhibitors can be used as valuable chemical
probes to help elucidate mechanisms of viral pathogenesis,
including host cellvirus interactions, Spike protein processing,
and ACE2 receptor binding. Since TMPRSS2 plays a key role
as a viral protein processing protease in the pathogenesis of
Mahoney et al.
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV
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TMPRSS2-Protease Domain Expression and Purification. Periplasm
secreted bacterial expression of serine proteases has been
widely reported to yield correctly folded high-quality enzyme
due to its reducing environment allowing for disulfide formation
and fewer proteases being present compared to the cytoplasm
(59, 60). We therefore employed a similar strategy for TMPRSS2
protease domain. The human TMPRSS2 extracellular domain
(residues 106 through 492) was cloned into a pET28a vector with
a pelB leader sequence followed by an N-terminal 6x His tag (SI
Appendix, Fig. S8A) using standard Gibson assembly procedures
(61). Escherichia coli DH5a cells were transformed with the Gibson assembly reaction mixture, and resulting plated colonies were
selected and verified with Sanger DNA sequencing for correct
assembly of the cloned product. Correctly cloned plasmid was
used for transforming E. coli BL21(DE3) cells and later used for
subsequent expressions. A single colony of BL21(DE3) cells
was picked and inoculated into 50 mL of luria broth (LB) with
2% glucose and 50 mg/mL Kanamycin culture and grown overnight at 37 ° C, 220 rpm. Liter-scale liquid media (LB 0.1%
glucose, 50 mg of Kanamycin) were inoculated with overnight
cultures at a starting optical density at a wavelength of 600 nm
(OD600) of 0.05, and expression was induced with a final concentration of isopropylthio-β-galactoside (IPTG) at 1 mM at OD600
of 0.7. Expressions were carried out at 16 ° C for ∼72 h. Cells
were collected by centrifugation, and the periplasmic extracts
were prepared by osmotic shock. Briefly, cell pellets were resuspended in TES buffer [200 mM TrisHCl pH 8, 0.5 mM (ethylenedinitrilo)tetraacetic acid, 500 mM sucrose] and incubated at
4 ° C for 1 h followed by addition of cold water and incubation at
4 ° C for 45 min. The periplasmic extract was isolated with centrifugation (10,000 × g for 30 min) at 4 ° C, and imidazole (10 mM
final concentration) and MgCl2 (100 mL/L expression culture volume) were added for overnight batch binding with Ni-NTA resin
(2 mL of slurry per liter of expression culture volume). Purification was carried out with 10 column volumes of Wash buffer 1
(50 mM Tris, 250 mM NaCl, pH 7.6) and, subsequently, 10 column volumes of wash buffer 2 (50 mM Tris, pH 7.6, 250 mM
NaCl, 20 mM imidazole) and eluted with elution buffer (50 mM
Tris, pH 7.6, 250 mM NaCl, 4 mM benzamidine, 1 mM CaCl2,
500 mM imidazole) (SI Appendix, Fig. S8C). SDS/PAGE was performed with fractions of eluate, and those showing the correctly
sized band for TMPRSS2 protease domain were pooled. Consolidated fractions were buffer exchanged against 25 mM Citrate pH
6, 250 mM NaCl, 4 mM benzamidine, 1 mM CaCl2 to remove
excess imidazole and prevent autolysis and concentrated down in
the same buffer with 10-kDa NMWL Amicon ultra filtration
units. Potential aggregates and degradation products were
removed by size exclusion chromatography with 25 mM Citrate
pH 6, 250 mM NaCl, 4 mM benzamidine, 1 mM CaCl2 and 10%
glycerol and Superdex 200 Increase 10/300 GL. TMPRSS2 protease domain containing fractions by SDS/PAGE (SI Appendix, Fig.
S8D) were pooled. A final Western blot against the protease
domain (TMPRSS2 monoclonal antibody [M05], clone 2F4) was
performed to verify the collected sample to be TMPRSS2 protease domain. The pooled sample was flash frozen for subsequent
assays (SI Appendix, Fig. S8E).
Recombinant enzyme inhibition assays. Recombinant human
TMPRSS2 was purchased from Cusabio Technology (CSBMahoney et al.
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV
viral entry and protect human epithelial lung cells

MSP-MS. Human recombinant TMPRSS2 (100 nM) expressed
in yeast (see Expression of Human Recombinant TMPRSS2 in
Pichia pastoris) was incubated at room temperature with a
physiochemically diverse library of 228 tetradecapeptides to a
final concentration of 500 nM. Aliquots were removed at different time intervals (15, 60, and 240 min) and subsequently
quenched with 1Eq volume of 8 M guanidinium hydrochloride.
Samples were desalted using C18 tips (Rainin) and analyzed by
liquid chromatography (LC)-MS/MS peptide sequencing using
a Quadrupole Orbitrap mass spectrometer (LTQ Orbitrap)
coupled to a 10,000-psi nanoACQUITY Ultra Performance
Liquid Chromatography System (Waters) for peptide separation by reverse phase LC. Peptides were separated over a
Thermo ES901 C18 column (75-μm inner diameter, 50-cm
length) coupled to an EASY-SprayTM ion source and eluted
by applying a flow rate of 300 nL/min in a 65-min linear gradient from 2 to 50% in Buffer B (acetonitrile, 0.5% formic acid).
Survey scans were recorded over a 325 m/z to 1,500 m/z range,
and up to three of the most intense precursor ions (MS1
features of charge ≥ 2) were selected for collision-induced dissociation. Data were acquired using Xcalibur software and
processed as previously described (62). Briefly, raw MS data
were processed to generate peak lists using MSConvert. Peak
lists were then searched in Protein Prospector v.6.2.2 (63)
against a database containing the sequences from the 228
tetradecapeptide library. Searches used a mass accuracy tolerance of 20 ppm for precursor ions and 0.8 Da for fragment
ions. Variable modifications included N-terminal pyroglutamate
conversion from glutamine or glutamate and oxidation of tryptophan, proline, and tyrosine. Searches were subsequently processed using the MSP-xtractor software (https://pharm.ucsf.edu/
craik/research/extractor), which extracts the peptide cleavage site
and spectral counts of the corresponding cleavage products. Spectral counts were used for the relative quantification of peptide
cleavage products.
Expression of Human Recombinant TMPRSS2 in Pichia pastoris.

Human recombinant TMPRSS2 was expressed and purified
from yeast following protocols previously described (30), with
slight modifications. Briefly, the SRCR and serine protease
domain regions of TMPRSS2-N249G were cloned into a
pPICZα-B construct (EasySelect Pichia Expression Kit;
PNAS j 9 of 12
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YP023924HU) and assayed in 25 mM TrisHCl, 150 mM NaCl,
5 mM CaCl2, 0.01% Triton X-100, pH 8.0 at a final concentration of 3 nM. To calculate KM, Boc-QAR-AMC (Vivitude,
MQR-3135-v) was serially diluted in dimethyl sulfoxide
(DMSO), and then each diluent was further diluted in assay
buffer such that the final substrate concentration in the assay
ranged from 0.514 μM to 200 μM with a final DMSO concentration of 0.5%. Assays were performed in a total volume of 30
μL in triplicate wells of black 384-well plates (Nunc 262260),
and initial velocity was measured in 35-s intervals for 7 min
with excitation of 360 nm and emission of 460 nm on a Biotek
HTX plate reader. KM and Vmax were calculated from Michaelis
Menten plots using GraphPad Prism. For inhibitor studies,
compounds were serially diluted threefold in DMSO and then
preincubated with TMPRSS2 in assay buffer for 30 min at
room temperature. The reaction was initiated following the
addition of Boc-QAR-AMC, and fluorescence was measured
in 190-s intervals for 90 min. The final concentrations of
enzyme and substrate were 3 nM and 86.6 μM, respectively,
and the inhibitor concentrations ranged from 2 μM to
0.15 pM. Assays were performed in quadruplicate plates, and
IC50 was calculated from dose–response curves using GraphPad Prism. IC50 values for HGFA, matriptase, hepsin, factor
Xa, and thrombin were determined using our published
assays (37–39).

CHEMISTRY

other coronaviruses (SARS-CoV, MERS-CoV) as well as influenza viruses (25, 54–58), MM3122 and this new class of inhibitors may be effective not only against COVID-19 but for
infections caused by most or all corona and influenza viruses.
Thus, these small-molecule inhibitors of TMPRSS2 not only
hold much promise as new drugs to treat SARS-CoV-2 infections but also potentially represent broad-spectrum antivirals.

Invitrogen) according to the manufacturer, transformed into P.
pastoris strain ×33, and selected on plates containing increasing
concentrations of Zeocin. A single colony was grown in 10 mL
of buffered medium with glycerol (BMGY) overnight at 30 ° C
and 230 rpm. The overnight culture was used to inoculate 1 L
of BMGY and grown until OD600 2 through 6. Cells were pelleted and resuspended in 100 mL of buffered medium with
methanol. Cells were induced with 5% methanol every 24 h for
72 h to 96 h. Secreted TMPRSS2 was precipitated with 70%
ammonium sulfate at 4 ° C overnight, pelleted at 27,000 × g for
45 min, and resuspended in 50 mM Tris pH 8, 0.5 M NaCl,
0.01% CHAPS, and solubilized for 2 h at 4 ° C. The solubilized
protein was then purified over a gravity column containing soybean trypsin inhibitor immobilized agarose (Pierce). TMPRSS2
was concentrated and then purified with size exclusion chromatography using 50 mM potassium 83 phosphate buffer, pH 6,
150 mM NaCl, 1% glycerol to prevent autoproteolysis.
Cell-based TMPRSS2 fluorogenic enzyme inhibition assay. A
PLX304 plasmid–containing human TMPRSS2 open reading
frame from the ORFeome Collaboration (Dana-Farber Cancer
Institute, Broad Institute of Harvard and Massachusetts Institute
of Technology [HsCD00435929]) was obtained from DNASU
Plasmid Repository, and a control PLX304 vector was obtained
from Addgene. HEK-293T cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and seeded in a black, 96-well plate (75,000
cells per well). The following day, cells were transfected overnight
with either a control plasmid (PLX) or TMPRSS2 (PLXTMPRSS2) via TransIT LT-1 transfection reagent (Mirus Bio) in
100 μL of OptiMEM per well. Twenty-four hours after transfection, the media was replaced with 80 μL of phosphate-buffered
saline (PBS). Inhibitors or PBS alone were added to the wells
in the indicated five concentrations and incubated at 25 ° C for
15 min. The fluorogenic substrate Boc-QAR-AMC (R&D Biosystems) was then added to each well to a final concentration of
100 μM. Fluorescence (excitation 365 nm, emission 410 nm) was
kinetically measured every 15 min for a total time of 150 min at
37 ° C using a GloMax plate reader (Promega).
Antiviral activity (VSV-SARS-CoV-2 and MERS chimeras). Viruses
used. VSV-eGFP, a recombinant VSV expressing a GFP reporter
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(depends on the VSV glycoprotein G for entry), has been previously described (64). VSV-SARS-CoV-2, a replication-competent
infectious VSV chimera which employs the SARS-CoV-2 Spike
(S) protein for viral entry in place of VSV G and expresses
eGFP, has also been previously described (41, 65). VSV-MERS
was created in the same manner as VSV-SARS-CoV-2, except
the MERS Spike missing the terminal 21 amino acids (HCoVEMC/2012 strain) was inserted in place of VSV G.
Experimental procedure. Human Calu-3 lung epithelial cells or
Vero cells (African green monkey kidney) were seeded in a
96-well black plate in DMEM containing 10% FBS for 24
h (37 ° C and 5% CO2). The next day, cells were pretreated for
2 h with inhibitor or vehicle control (DMSO) in 50 μL of
serum-free DMEM, and subsequently infected with VSVSARS-CoV-2, VSV-MERS, or VSV-eGFP at a multiplicity of
infection (MOI) of 0.5. At 7 h postinfection (single round of
infection), cells were fixed in 2% formaldehyde, and nuclei was
stained with 10 μg/mL Hoechst 33342 (Invitrogen) for 30 min
at room temperature. Cells were washed once and stored in
PBS after fixation, and automated microscopy was performed
using an InCell 2000 Analyzer (GE Healthcare) in the DAPI
and fluorescein isothiocyanate (FITC) channels (10× objective,
nine fields per well, covering the entire well). Images were analyzed using the Multi Target Analysis Module of the InCell
Analyzer 1000 Workstation Software (GE Healthcare) to identify the percentage of GFP-positive cells in each well (top-hat
segmentation). The percentage GFP-positive cells for
10 of 12 j PNAS
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experimental conditions was normalized against the control
(DMSO treated) cells and expressed as relative infectivity.
GraphPad Prism (version 8.4.2) was used to calculate the EC50
of each drug. Statistics (comparison of VSV-SARS-CoV-2 to
VSV-eGFP with each drug; Student’s t test) were performed in
Microsoft Excel. Three biological replicates were performed.
Antiviral activity (VSV pseudotype SARS-CoV-2). We analyzed
pseudotype entry driven by the spike protein of SARS-CoV-2
(SARS-2-S) or the glycoprotein of vesicular stomatitis virus
(VSV-G) into the TMPRSS2-positive human lung cell line
Calu-3 (7, 29). VSV-G was used as a control, as it does not
depend on TMPRSS2 for host cell entry. Besides Calu-3 cells,
we further used Vero cells (African green monkey, kidney) as a
control, as these cells do not express TMPRSS2, and therefore
any reduction in SARS-2-Sdriven entry would be related to
either unspecific side effects or cytotoxicity. Each compound
was tested in three separate experiments with independent
pseudotype batches. We treated cells (96-well format) with different concentrations of inhibitor or solvent (DMSO) diluted in
medium (50 μL per well) for 2 h at 37 ° C and 5% CO2, then we
added 50 μL of pseudotype on top and incubated for 16 h at
37 ° C and 5% CO2. Next, we measured virus-encoded firefly
luciferase activity in cell lysates (indicator of pseudotype entry
into target cells). The data were normalized against control
(DMSO-treated cells = 100% pseudotype entry) and plotted
with GraphPad Prism (version 8.3.0), to calculate effective concentration EC50 and perform statistics (comparison against the
respective control; two-way ANOVA with Dunnett’s posttest).
Antiviral activity (wild-type SARS-CoV-2). We seeded Calu-3
cells onto a white, flat bottom 96-well plate at 10,000 cells per
well in DMEM supplemented with 10% heat-inactivated FBS,
100 U/mL Penicillin-Streptomycin (Life Technologies, Inc.,
15140-163), and buffered with 10 mM Hepes and incubated in
a humidified 5% CO2 incubator at 37 ° C. Sixteen hours later,
the media was removed and replaced with the 50 μL per well of
the same media but containing 2% heat-inactivated FBS (D-2)
instead of 10%. In D-2, compounds were serially diluted threefold in a nine-point series and added in a 25-μL volume to the
96-well plate to make final concentrations ranging from 50 μM
to 7.6 nM on the assay plate for 1 h. We then infected the cells
(with compounds still on them) with 25 μL per well of SARSCoV-2 at an MOI of 0.1 plaque forming units (PFU) per cell,
with a final total volume of 100 μL per well. We incubated the
plates for 72 h as described above and then added 25 μL per
well of CellTiter-Glo Reagent (prepared as directed by manufacturer; Promega, G7573), followed by 5 min of shaking and
20 min of room temperature incubation before detecting luminescence with a Biotek Synergy H1 plate reader. Compound
cytotoxicity was determined using the same assay, but, instead
of adding virus, we added 25 μL of D-2. These experiments
were performed three times, and we performed nonlinear
regression on log(inhibitor) vs. response with variable slope
and four parameters on compiled results from the three experiments. Likewise, IC50s were calculated based on all three biological replicates.
Animal Studies. All animal procedures were performed following
the guidelines and approval of the Washington University’s
Institutional Animal Care and Use Committee. Animals were
maintained in a controlled temperature (22 ° C 6 0.5 ° C) and
lighting (12 L:12 D) environment. Standard laboratory chow
and water were supplied ad libitum.
Mouse Toxicity Studies. NOD-scid IL2Rgnull (NSG) male and
female mice (three per group) were injected with 0, 20, 50, or
100 mg/kg MM3122 (in 1 to 5% DMSO/95% saline; IP) daily
for 7 d. Animal health was assessed daily for drug toxicity
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Data Availability. All study data are included in the article and SI Appendix.

Supplementary Data. Single point inhibition data using recombinant protease domain with FRET substrate for 4 through 6 are
provided in SI Appendix, Fig. S1. Protease selectivity data for 1
(ZFH7116) and 2 (VD2173) are provided in SI Appendix,
Tables S1 and S2. Synthesis and NMR and high-performance
liquid chromatography mass spectrometry (HPLC-MS) spectra
of new compounds 2, 4 through 7, and 19 through 21 are provided in SI Appendix, Schemes S1–S3. Km curve for Boc-QARAMC using full-length TMPRSS2 is provided in SI Appendix,
Fig. S2. IC50 inhibition curves of full-length TMPRSS2/Boc-
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Mouse PK Studies. MM3122 was tested for its PK in mice (single
IP dosing, actual dose 16.7 mg/kg). Eight animal groups contained three animals each (male, CD-1), with plasma drawn
and lung tissue harvested at eight different sampling time
points (0.08, 0.25, 0.5, 1, 2, 4, 8, and 24 h) post dosing. VD2173
was tested for its PK in mice (single IP dosing, actual dose 16.7
mg/kg). Three animal groups contained three animals each
(male, CD-1), with plasma drawn and lung tissue harvested
from each group of animals at three different sampling time
points (0.25, 8, and 24 h) post dosing. Bioanalysis of plasma
and lung tissue extracts were performed using standard LC/MS/
MS techniques.

QAR-AMC are provided in SI Appendix, Fig. S3. Cell-based
enzyme activity of compounds 1 and 2 in HEK-293 cells is provided in SI Appendix, Fig. S4. Acute toxicity of MM3122 (4) is
provided in SI Appendix, Fig. S5. Activity of 1 and 2 and Camostat using Vero cells in pseudotype is provided in SI Appendix,
Fig. S6 and in chimeric VSV-SARS-CoV-2 viruses in SI
Appendix, Fig. S7. Expression and purification of the TMPRSS2
protease domain are provided in SI Appendix, Fig. S8.
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(ruffled fur, discharge from the eyes, weight loss, dehydration,
lethargy, hypothermia, abnormal tissue growth), and body
weights were measured every 2 d to 3 d. At the end of the
experiment, animals were killed, and organs were inspected.
Liver, spleen, and both kidneys were collected and weighed.
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